Negroni R, Palmieri O, Koren F, Tiraboschi I N, Galimberti R L
Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S47-50. doi: 10.1093/clinids/9.supplement_1.s47.
Twenty-five patients with paracoccidioidomycosis and 17 patients with histoplasmosis were treated with itraconazole. All patients were adults. Those with paracoccidioidomycosis exhibited the chronic disseminated form of the disease; 21 of these patients had lesions in two or more locations, and four had lesions only on the larynx or mouth. Itraconazole was administered at a daily dosage of 50 mg for six months in the majority of these cases. All infections were clinically cured or showed striking improvement. Patients with histoplasmosis had the chronic pulmonary or chronic disseminated form of the disease. A daily dose of 100 mg was administered until clinical cure was established; the dose was then changed to 50 mg until the completion of six months of treatment. Twelve infections were clinically cured; four were strikingly alleviated. The remaining patient, who discontinued treatment with itraconazole after two months, had a severe relapse and died of respiratory failure.
25例副球孢子菌病患者和17例组织胞浆菌病患者接受了伊曲康唑治疗。所有患者均为成年人。副球孢子菌病患者表现为慢性播散型疾病；其中21例患者的病变位于两个或更多部位，4例患者仅喉部或口腔有病变。在大多数此类病例中，伊曲康唑的每日剂量为50mg，持续6个月。所有感染均临床治愈或显著改善。组织胞浆菌病患者表现为慢性肺部或慢性播散型疾病。每日剂量为100mg，直至确立临床治愈；然后将剂量改为50mg，直至完成6个月的治疗。12例感染临床治愈；4例显著缓解。其余1例患者在接受伊曲康唑治疗两个月后停药，出现严重复发并死于呼吸衰竭。
